FDA EIR - Morton Salt Inc - May 24, 2017

A routine comprehensive FDA inspection of Morton Salt Inc's Rittman, Ohio facility was conducted from May 23-24, 2017. The inspection, part of the FDA's FY '17 Food Workplan focusing on Modernized Good Manufacturing Practices (GMP) for human food products, aimed to assess the facility's adherence to regulatory standards. Morton Salt Inc manufactures salt and spice blends for human consumption, animal salt blocks, and USP salt. During the two-day inspection, no formal Inspectional Observations (FDA-483) were issued, signifying a high level of compliance. However, one discussion item was raised concerning facility maintenance: two dock doors in the shipping area were found to be in disrepair, exhibiting gaps at the bottom and rust. The regulatory framework guiding this inspection was the FY '17 Food Workplan and the Modernized GMP Inspections. The company also confirmed its registration under the Bioterrorism Act. In response to the identified issue, company management, including the General Manager and Quality Manager, promptly committed to repairing the compromised dock doors within one week and indicated that replacement would be considered if necessary. Management was receptive to the findings, and the inspection concluded without any significant regulatory actions required, beyond the discussed repair.